Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)-Reference-Cited by-同舟云学术

Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)

Published:2020-12-24 Issue:1 Volume:64 Page:644-661
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Cheng Hengmiao¹^ORCID,Orr Suvi T. M.¹,Bailey Simon¹,Brooun Alexei¹,Chen Ping¹,Deal Judith G.¹,Deng Yali L.¹,Edwards Martin P.¹,Gallego Gary M.¹,Grodsky Neil¹,Huang Buwen¹,Jalaie Mehran¹,Kaiser Stephen¹,Kania Robert S.¹,Kephart Susan E.¹,Lafontaine Jennifer¹,Ornelas Martha A.¹,Pairish Mason¹,Planken Simon¹^ORCID,Shen Hong¹,Sutton Scott¹,Zehnder Luke¹,Almaden Chau D.¹,Bagrodia Shubha¹,Falk Matthew D.¹,Gukasyan Hovhannes J.¹,Ho Caroline¹,Kang Xiaolin¹,Kosa Rachel E.¹,Liu Ling¹,Spilker Mary E.¹,Timofeevski Sergei¹,Visswanathan Ravi¹,Wang Zhenxiong¹,Meng Fanxiu²,Ren Shijian²,Shao Li²,Xu Feng²,Kath John C.¹

Affiliation:

1. La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States

2. Wuxi AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.0c01652

Reference34 articles.

1. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

2. The PI3K Pathway in Human Disease